Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
- Recently announced positive Phase 2 topline data in Major Depressive Disorder with 79% of patients in remission from depression after two doses of CYB003 - - Programs supported by robust...
United States United Kingdom Doug Drysdale Health Canada Exchange Commission Deuterated Psilocybin Analog Program For The Treatment
Source: marketscreener.com